2. Treatment-related adverse events grade 3-5 occurred in 38.7% of the belzutifan group and 39.4% of the everolimus group. Evidence Rating Level: 1 (Excellent) Study Rundown: Antiangiogenic and immune ...
Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...
Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.